Global Pharma Supply Chain - Competitive Risk Assessment

Tariffs, Trade Policy, and the Global Pharma Supply Chain: A Competitive Risk Assessment

As global trade dynamics shift yet again, the pharmaceutical industry is bracing for impact. Recent tariff developments—particularly the reintroduction of sweeping U.S. import duties—are prompting executives across healthcare and life sciences to revisit their sourcing strategies and cost structures. But…

why the neuroscience resurgence

Why the Neuroscience Resurgence—Especially in Alzheimer’s and Parkinson’s—Is a Call for Smarter Competitive Intelligence

I’ll admit it—there was a time when neuroscience felt like a graveyard of pharma ambitions. I remember the wave of program terminations, the clinical failures, and the retreat from Alzheimer’s and Parkinson’s pipelines that felt almost industry wide. For a…

Drug Pricing Reform - Competitive Intelligence

U.S. Drug Pricing Reform: How It Will Reshape the Pharmaceutical Landscape and the Role of Competitive Intelligence

Introduction Background Drug pricing reform in the U.S., driven by legislative changes such as the Inflation Reduction Act (IRA) and ongoing policy initiatives, is set to significantly alter the pharmaceutical competitive landscape. These changes will influence market access, pricing strategies,…